Skip to main
CAPR

Capricor Therapeutics (CAPR) Stock Forecast & Price Target

Capricor Therapeutics (CAPR) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Capricor Therapeutics Inc. is experiencing a substantial increase in its assessed value for deramiocel, now estimated at $2.30 billion, reflecting a significant growth from the previous valuation of $794 million. Positive Phase III clinical data for deramiocel indicates improvements in patient outcomes, such as a 1.0 point enhancement in the PUL 2.0 Mid-level Dimension and notable advancements in cardiac health metrics. With anticipated revenue growth through strategic partnerships, including the NSPharma collaboration, Capricor Therapeutics demonstrates promising potential for future net sales, further enhancing the company's financial outlook.

Bears say

Capricor Therapeutics faces significant challenges related to the clinical viability of its product deramiocel, which may encounter substantial hurdles regarding safety, efficacy, and regulatory approval. The company's financial outlook may be further hampered by a slower-than-anticipated market penetration rate, which could require additional financing under unfavorable terms, potentially leading to equity dilution. Additionally, the declining left ventricular ejection fraction (LVEF) in Duchenne muscular dystrophy patients highlights the urgency of intervention, yet the therapeutic market potential may ultimately fall short of initial projections, contributing to a negative outlook for the company's stock.

Capricor Therapeutics (CAPR) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Capricor Therapeutics (CAPR) Forecast

Analysts have given Capricor Therapeutics (CAPR) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Capricor Therapeutics (CAPR) has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Capricor Therapeutics (CAPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.